REFERENCES
- Attarbaschi A, Mann G, König M, et al. Incidence and Au: Update? relevance of secondary chromosome abnormalities in childhood TEL/AML1+ acute lymphoblastic leukemia: an interphase FISH analysis. Leukemia 2004, in press
- Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 1997; 90: 571–577, [PUBMED], [INFOTRIEVE], [CSA]
- Golub T R, Barker G F, Bohlander S K, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1995; 92: 4917–4921, [PUBMED], [INFOTRIEVE], [CSA]
- Loh M L, Rubnitz J E. TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. Curr Opin Hematol 2002; 9: 345–352, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Seeger K, Adams H P, Buchwald D, et al. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin–Frankfurt–Munster Study Group. Blood 1998; 91: 1716–1722, [PUBMED], [INFOTRIEVE], [CSA]
- Hasle H, Clemmensen I H, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000; 355: 165–169, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Loncarevic I F, Roitzheim B, Ritterbach J, et al. Trisomy 21 is a recurrent secondary aberration in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion, Genes Chromosomes. Cancer 1999; 24: 272–277
- Lanza C, Volpe G, Basso G, et al. The common TEL/AML1 rearrangement does not represent a frequent event in acute lymphoblastic leukaemia occuring in children with Down syndrome. Leukemia 1997; 11: 820–821, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chessells J M, Harrison G, Richards S M, et al. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child 2001; 85: 321–325, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Schrappe M, Reiter A, Ludwig W D, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German–Austrian–Swiss ALL-BFM Study Group. Blood 2000; 95: 3310–3322, [PUBMED], [INFOTRIEVE], [CSA]
- Attarbaschi A, Mann G, Dworzak M, et al. Treatment results of childhood acute lymphoblastic leukemia in Austria: a report of 20 years’ experience. Wien Klin Wochenschr 2002; 114: 148–157, [PUBMED], [INFOTRIEVE]
- van der Does-van den Berg A, Bartram C R, Basso G, et al. Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the “BFM Family” Cooperative Group. Med Pediatr Oncol 1992; 20: 497–505, [PUBMED], [INFOTRIEVE]
- Drabkin H A, Erickson P. Down syndrome and leukemia, an update. Prog Clin Biol Res 1995; 393: 169–176, [PUBMED], [INFOTRIEVE], [CSA]
- Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 2000; 110: 512–524, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Nucifora G, Rowley J D. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995; 86: 1–14, [PUBMED], [INFOTRIEVE], [CSA]
- Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryo-cytic malignancies associated with trisomy 21. Blood 2003; 102: 981–986, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gurbuxani S, Vyas P, Crispino J D. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood 2004; 103: 399–406, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood 2004; 103: 2480–2489, [PUBMED], [INFOTRIEVE], [CROSSREF]